MASSACHUSETTS CANCER REGISTRY

Abstracting and Coding Manual For Hospitals

Third Edition April 1999

Commonwealth of Massachusetts Department of Public Health Howard K. Koh, M.D., M.P.H. Commissioner

Bureau of Health Statistics, Research and Evaluation Daniel J. Friedman, Ph.D. Assistant Commissioner

Massachusetts Cancer Registry Susan T. Gershman, M.S., M.P.H., Ph.D., C.T.R. Director

Prepared by:

Carol L. Lowenstein, M.B.A., C.T.R. Assistant Director, Registry Operations

with Mary Mroszczyk, C.T.R.

Acknowledgments

Special thanks are given to Massachusetts Cancer Registry staff who painstakingly reviewed this Manual --

Nancylee Campbell, C.T.R.
Roberta McLaughlin, A.R.T., C.T.R.
David Rousseau, B.S.

Thanks also to demographer Alison Donta for obtaining our Spanish/Hispanic surname list, Dianne Hultstrom for her assistance with coding clarifications, and the many other individuals who contributed to the preparation of this Manual.

Additional copies of this manual can be obtained by contacting:

Mass. Dept. of Public Health
Mass. Cancer Registry
250 Washington St, 6th Flr
Boston, MA 02108-4619
(617) 624-5645 / fax (617) 624-5697

CONTENTS

<u>page</u>
PREFACE TO THE THIRD EDITIONi
SECTION I INTRODUCTION
Introductory Note1
Confidentiality2
Casefinding3
Reporting Requirements
Reporting Methods4
Changes to Previously Submitted Forms4
MCR Cancer Patient Abstract6
MCR Change / Delete Form7
References8
Abstracting Requirements for Nonanalytic Cases
SECTION II REPORTABILITY
Determining Reportability11
Definition of a Cancer Diagnosis11
Identification of the Primary Neoplasm12
Single-Versus-Multiple Primaries
Related Definitions14
Single Primaries
Multiple Primaries17
Paired Organs (Laterality)18
Breast Ductal and Lobular Carcinomas19
Intraductal Carcinoma and Paget's Disease
Kaposi's Sarcoma19
Lymphatic and Hematopoietic Diseases20
Negative Biopsies40
Pathology-Only and Consultation-Only Cases40

TION III	I PATIENT INFORMATION	page
	lity Name	<i>1</i> 1
	lity Code	
	ession Number	
	ience Number	
-	Malignant Tumors	
	Nonmalignant Tumors	
	First Seen for This Primary	
	nary Payer at Diagnosis	
	ical Record Number	
	racted By	
	ission Date	
	harge Date	
	aging Physician Name	
	aging Fnysician Nament Name	
	Last Name	
	Suffix	
	First Name.	
	Viiddle Name	
	Maiden Name	
	Alias	
	n Date	
U	at Diagnosis	
	nplace	
	al Security Number	
	ess at Diagnosis	
	Street Address	
	City / Town	
	State	
	ZIP / Postal Code	
	ital Status at Diagnosis	
wari	ital Status at Diagnosis	39

page
Spanish/Hispanic Origin62
Surnames / Maiden Names
Tobacco History67
Occupation and Industry68
Usual Occupation70
Usual Industry / Type of Business70
SECTION IV TUMOR DATA
Primary Site Code73
Site-Specific Morphologies
Primary-Versus-Secondary (Metastatic) and Ill-Defined Sites74
Special Primary Site Conditions
Laterality76
Narrative Primary Site78
Histology / Behavior / Grade79
Histologic Type Code79
Behavior Code83
Grade / Differentiation / Cell Origin Code86
Narrative Histology/Behavior/Grade90
Date of Diagnosis90
Class of Case92
Tumor Size 94
Confirmation Method99
Type of Reporting Source101
AJCC TNM Staging System102
Clinical T 104
Clinical N 107
Clinical M 109
Clinical TNM Stage Grouping112
Pathologic T114
Pathologic N117
Pathologic M119
Pathologic TNM Stage Grouping122
TNM Edition Number124

<u>pa</u>	age
SEER General Summary Stage 12	25
Pediatric Stage13	32
Pediatric Staging System13	34
Regional Nodes Examined	35
Regional Nodes Positive13	37
Narrative Staging13	39
SECTION V TREATMENT DATA	
First Course of Treatment - General Instructions	11
Treatment Plan14	11
Time Periods for All Malignancies Except Leukemia14	11
Time Periods for Leukemia	12
Definitions	12
Treatment Data Items	13
Non Cancer-Directed Surgery14	14
Non Cancer-Directed Surgery Summary14	15
At This Facility14	16
Date Started14	16
Cancer-Directed Surgery	17
Surgical Approach14	17
Surgery of Primary Site Summary15	51
At This Facility15	51
Date Started15	51
Narrative15	51
Surgical Margins15	52
Scope of Regional Lymph Node Surgery Summary15	53
At This Facility15	53
Number of Regional Lymph Nodes Removed Summary 15	54
At This Facility15	54
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes Summary	55
At This Facility15	
Reconstruction / Restoration First Course	
Reason For No Cancer-Directed Surgery15	

	<u>page</u>
Radiation Therapy	158
Summary	160
At This Facility	160
Date Started	161
Narrative	161
Radiation / Surgery Sequence	161
Chemotherapy	162
Summary	164
At This Facility	164
Date Started	165
Narrative	165
Hormone / Steroid / Endocrine Therapy	166
Summary	168
At This Facility	168
Date Started	168
Narrative	168
Immunotherapy	169
Summary	170
At This Facility	170
Date Started	171
Narrative	171
Other Cancer-Directed Therapy	172
Summary	173
At This Facility	173
Date Started	174
Narrative	174
SECTION VI FOLLOW-UP DATA	
Date of Last Contact	175
Vital Status	175
Place of Death	176
Comments / Narrative Remarks	176

SECTION	VII CASE STATUS INFORMATION	page
	te Case Completed	177
	te Case Report Exportedndor Name / Version Number	
v e	ndor Name / Version Number	1//
APPENDIC	CES	
A.	Codes for Birthplace and Place of Death	
В.	Paired Organ Sites	
C.	Common Acceptable Abbreviations	
D.	Cancer-Directed Surgery Codes	
INDEX		
List of Tab		
Table I	fields deleted, changed or added since previous edition	ii
Table II.1	ICD-O-2 codes considered one primary site	16
Table II.2	single/multiple primaries for lymphatic and hematopoietic diseases	21
Table III	common codes for the State at Diagnosis field	58
Table IV.1	paired organ sites	77
Table IV.2	millimeter equivalents of descriptive terms	96
	ons Repeated in this Manual	
ACoS	American College of Surgeons	
AJCC	American Joint Committee on Cancer	
aka BRM	also known as biological response modifier	
CT	computed tomography scan	
DPH	Massachusetts Department of Public Health	
ICD-O-2	World Health Organization's International Classification of Dis	seases for Oncology
	Second Edition	
MCR	Massachusetts Cancer Registry	
MRI	magnetic resonance imaging	
NAACCR	North American Association of Central Cancer Registries	
NOS	not otherwise specified	
PET SEER	positron emission tomography scan	Doculta program
TNM	National Cancer Institute's Surveillance, Epidemiology and End staging system of the American Joint Committee on Cancer's <i>Ca</i>	
T 1 414T	Manual, Fifth Edition	ancer singing

PREFACE TO THE THIRD EDITION

This Third Edition of the Massachusetts Cancer Registry *Abstracting and Coding Manual for Hospitals* is a revision of the Second Edition of the manual which was published in 1995. In light of updates and clarifications needed to the original manual and the coding changes beginning with 1998 data, it was felt that a third edition was necessary.

The Massachusetts Cancer Registry (MCR) continues to strive for compatibility with the coding and abstracting practices of the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program, the Centers for Disease Control and Prevention's National Program of Cancer Registries (CDC/NPCR), the North American Association of Central Cancer Registries (NAACCR), and the American College of Surgeons (ACoS). Compatibility with these groups assures consistent coding and allows Massachusetts hospitals and the MCR to compare data with other states and the nation as a whole.

The Massachusetts Cancer Registry Cancer Information Management System (MCR-CIMS) has been revised to accommodate the changes in this manual. Vendors of software reporting programs have also been informed of these changes.

The codes in this edition are to be used for cases diagnosed as of anuary 1, 1998. Pre-1998 cases that have already been abstracted should be re-coded. A copy of the second edition of this manual should be retained in each hospital registry for reference.

The format of this manual has been designed for placement in a three-ring binder which will allow the MCR to update the text easily. As changes are made, updated replacement pages will be sent to all hospitals so that each copy of the *Manual* will remain consistent with current abstracting and coding procedures.

The following is a summary of the fields that have been deleted, changed or added since the previous edition of the *Manual*:

Table I

Data Field	Comments
Accession Number (p. 41)	New item for the MCR. Unique number assigned to each patient by the reporting facility.
Sequence Number (p. 42)	New alphabetic codes introduced for non-malignant cases.
Year First Seen for This Primary (p. 45)	New item for the MCR. This is the year the patient was first seen at the reporting institution for diagnosis and/or treatment of the reported primary.
Primary Payer at Diagnosis (p. 46)	New item for the MCR. This field distinguishes the major source of payment for this cancer case when originally diagnosed (HMO, self-paid, Medicare, etc.)
Abstracted By (p. 47)	New item for the MCR. Three-character field to be used for the reporting hospital abstractor's initials.
Managing Physician Name (p. 48)	No change, but field is not divided into last/first/middle on MCR paper abstract. Note: text not a code is entered.
Patient Name: Suffix (p. 49)	New item for the MCR. Provides a field for the title that may follow a patient's last name, such as generational order (Jr./Sr./III) and credential status.
Patient Middle Name (p. 50)	Field expanded to accommodate the entire middle name.
Patient Name: Alias (p. 51)	New item for the MCR. Records an alternate or "aka" name used by the patient.
Address at Diagnosis - State (p. 57)	New codes for foreign addresses.
Address at Diagnosis ZIP/Postal Code (p. 57)	Definitions of codes 88888888 and 999999999 revised.
Patient Race: If Other Race, Specify	This field has been eliminated
Spanish/Hispanic Origin (p. 62)	Change in definition of code 7.
Tobacco History (p. 67)	New name for the Smoking Status field. No coding change since new codes introduced for cases diagnosed as of 1/1/96.

Table I (cont.)

Data Field	Comments
Primary Site Code (p. 73)	ICD-O-2 topography code C14.1 (Laryngopharynx) no longer used (This is now a synonym for Hypopharynx, NOS C13.9.)
Histologic Type Code (p. 79)	New ICD-O-2 codes added since 1995 (9715, 9688, 9708, 9710, 9716, 9717, 9828, 9871, 9872, 9873, 9874).
Grade/Differentiation/Cell Origin (p. 86)	New code 8 (natural killer cell origin).
Class of Case (p. 92)	Addition of Class 6 cases.
Type of Reporting Source (p. 101)	New name for the Place of Diagnosis field.
TNM fields	Clinical and Pathologic classifications collected separately.
Staging Basis	This field has been eliminated
Clinical TNM Elements (pp. 104-111)	New AJCC Cancer Staging Manual, 5th ed. codes.
Clinical Stage Grouping (p. 112)	New AJCC Cancer Staging Manual, 5th ed. codes.
Pathologic TNM Elements (pp. 114-121)	New AJCC Cancer Staging Manual, 5th ed. codes.
Pathologic Stage Grouping (p. 122)	New AJCC Cancer Staging Manual, 5th ed. codes.
TNM Edition Number (p. 124)	New item for the MCR. Identifies the edition number of the <i>AJCC Cancer Staging Manual</i> used to stage the case.
Pediatric Stage (p. 132)	New item for the MCR. Used to record the pediatric stage as specified in the pediatric staging system selected.
Pediatric Staging System (p. 134)	New item for the MCR. Specifies the type of staging system used to stage a pediatric case.
Regional Nodes Examined (p. 135)	New item for the MCR. Describes the total number of regional lymph nodes examined by a pathologist during first course of treatment.
Regional Nodes Positive (p. 137)	New item for the MCR. Describes the total number of regional nodes examined by the pathologist during first course of treatment and reported as containing tumor.
Narrative Staging (p. 139)	New item for the MCR. Text field to support stage codes.

Table I (cont.)

Data Field	Comments
Non Cancer-Directed Surgery Summary (p. 145)	New item for the MCR (was collected previously only if no cancer-directed surgery was done). Codes the procedures performed at all facilities to diagnose/stage disease or for relief of symptoms.
Non Cancer-Directed Surgery At This Facility (p. 146)	New item for the MCR (was collected previously only if no cancer-directed surgery was done at the reporting facility). Describes the procedures performed at the reporting facility to diagnose/stage disease or for relief of symptoms.
Non Cancer-Directed Surgery Date (p. 146	New item for the MCR. Specifies the date of non-cancer directed surgery.
Surgical Approach (p. 147)	New item for the MCR. This field describes the method used to approach the organ of origin and/or primary tumor.
Surgery of Primary Site - Summary (p. 151) New item (replaces Surgery-Summary) and new codes.
Surgery of Primary Site At This Facility (p. 151)	New item (replaces Surgery-This Hosp). This field also has new codes .
Surgery of Primary Site Narrative (p. 151)	Includes both Cancer-Directed and Non Cancer-Directed Surgery.
Surgical Margins (p. 152)	New item for the MCR. Describes the status of the surgical margins after resection of the primary tumor.
Scope of Regional Lymph Node Surgery Summary (p. 153)	New item for the MCR. Defines the removal of regional lymph nodes during primary site surgery.
Scope of Regional Lymph Node Surgery At This Facility (p. 153)	New item for the MCR. Defines the removal of regional lymph nodes at your facility during primary site surgery.
Number of Regional Lymph	New item for the MCR. Specifies the number of lymph
Nodes Removed Summary (p. 154)	nodes removed during the procedure coded in Surgery of Primary Site Summary.
Number of Regional Lymph Nodes	New item for the MCR. Specifies the number of lymph nodes
Removed At This Facility (p. 154)	removed during the procedure coded in Surgery of Primary Site At This Facility.



Table I (cont.)

	Tubic I (cont.)
<u>Data Field</u>	<u>Comments</u>
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes Summary (p. 155)	New item for the MCR. Describes the overall removal of tissue(s) or organ(s) other than the primary tumor or organ of origin.
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes At This Facility (p. 155)	New item for the MCR. Describes the removal of tissue(s) or organ(s) other than the primary tumor or organ of origin at your facility.
Reconstruction / Restoration First Course (p. 156)	New item for the MCR. Used to code reconstructive procedures during first course of treatment.
Radiation Therapy Summary (p. 160)	Code changes
Radiation Therapy At This Facility (p. 160)	Code changes
Radiation to CNS	This field has been eliminated
Radiation / Surgery Sequence (p. 161)	New name for Radiation Sequence.
Chemotherapy Summary (p. 164)	Code changes
Chemotherapy At This Facility (p. 164)	Code changes
Hormone Therapy Summary (p. 168)	Code changes , endocrine surgery/radiation no longer applies to breast primaries.
Hormone Therapy At This Facility (p. 168)	Code changes , endocrine surgery/radiation no longer applies to breast primaries.
Immunotherapy Summary (p. 170)	New codes.
Immunotherapy At This Facility (p. 170)	New codes.
Place of Death (p. 176)	New code 997 for patients alive on their Date of Last Contact.
Comments / Narrative Remarks (p. 176)	New name for the Comments field. Text used to convey any special circumstances or comments about the case. The field now appears on the front of the MCR paper abstract.

Table I (cont.)

<u>Data Field</u>	<u>Comments</u>
Date Case Completed (p. 177)	New item for the MCR. Date the case report was completed and passed all edits that were applied at the hospital level.
Date Case Report Exported (p. 177)	New item for the MCR. Date the reporting facility exports the electronic abstract to a file for transmission to the State.
Vendor Name / Version Number (p. 177)	New item for the MCR. Used to specify hospital software vendor and version number.

The goal of this manual is to establish common data standards governing the collection of cancer data throughout the Commonwealth of Massachusetts so as to ensure uniform reporting of statewide cancer statistics.

This manual is designed to be a working document that will change continually to reflect changes that occur in medical practice. Many of the suggestions and comments sent regarding the second edition have been incorporated in this manual. The MCR welcomes your questions, comments and suggestions. Please direct these to:

David Rousseau Quality Assurance Coordinator MDPH Mass. Cancer Registry 250 Washington St., 6th Floor Boston, MA 02108-4619 (617) 624-5656

April 1999